Skip to main content

Advertisement

SpringerLink
Log in

Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

A Correction to this article was published on 22 September 2018

This article has been updated

Abstract

Our aim was to retrospectively assess the role of golimumab as a treatment choice in patients with Behçet’s disease (BD). Seventeen patients diagnosed with BD according to the international criteria were consecutively enrolled; the BD Current Activity Form (BDCAF) was used to evaluate disease activity. After having collected clinical data from patients, statistical analysis was performed to identify differences between the start of therapy and last visit; significance was defined as p < 0.05. The mean duration of golimumab treatment was 18.47 ± 20.8 months. At the time of data enrollment, 12/17 (70.6%) patients were still on golimumab therapy. The mean time required to obtained clinical response was 4.9 ± 5.7 weeks. At 3 months evaluation, golimumab was able to control BD-related manifestations in 16/17 (94.1%) cases; the BDCAF values were significantly decreased at the last follow-up compared to those assessed at the start of golimumab (p = 0.002). The BDCAF improvement was significantly higher among patients co-administered with DMARDs than those undergoing golimumab as monotherapy (p = 0.048). At the last follow-up visit, corticosteroids had been discontinued in 10 (58.8%) patients, while the corticosteroid dosage was significantly lower at the last follow-up visit compared to the start of therapy in those patients already on corticosteroids at the end of the study (p = 0.001). Golimumab is a promising and safe treatment opportunity in BD patients with different systemic involvement, inducing a prompt resolution of clinical manifestations, a meaningful improvement of BDCAF score, and a significant corticosteroid-sparing effect. However, golimumab co-administered with DMARDs has provided better results than in patients undergoing monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

  • 22 September 2018

    In the original version of this article the author name Gerardo Di Scala was originally presented incorrectly as ‘Di Scala Gerardo’; this has been corrected in this article.

  • 22 September 2018

    In the original version of this article the author name Gerardo Di Scala was originally presented incorrectly as ?Di Scala Gerardo?; this has been corrected in this article.

References

  1. Alpsoy E (2016) Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43:620–632. doi:10.1111/1346-8138.13381

    Article  CAS  PubMed  Google Scholar 

  2. Rotondo C, Lopalco G, Iannone F et al (2015) Mucocutaneous involvement in Behçet’s disease: how systemic treatment has changed in the last decades and future perspectives. Mediat Inflamm 2015:451675. doi:10.1155/2015/451675

    Article  CAS  Google Scholar 

  3. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2015) Behçet’s syndrome: a critical digest of the 2014-2015 literature. Clin Exp Rheumatol 33:S3–14

    PubMed  Google Scholar 

  4. Criteria for diagnosis of Behçet’s disease (1990) International study Group for Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  5. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD) (2014) The international criteria for Behçet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347. doi:10.1111/jdv.12107

    Article  Google Scholar 

  6. Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR (2007) Cross-cultural adaptation of the Behçet’s disease Current activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263–1267

    Article  CAS  Google Scholar 

  7. Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67:1656–1662. doi:10.1136/ard.2007.080432

    Article  CAS  PubMed  Google Scholar 

  8. Vitale A, Rigante D, Caso F et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology 228:211–214. doi:10.1159/000358125

    Article  PubMed  Google Scholar 

  9. Cantarini L, Vitale A, Scalini P et al (2015) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 34:1293–1301. doi:10.1007/s10067-013-2443-8

    Article  PubMed  Google Scholar 

  10. Vitale A, Insalaco A, Sfriso P et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 7:380. doi:10.3389/fphar.2016.00380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cantarini L, Stromillo ML, Vitale A et al (2016) Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet’s disease with different organ involvement: a case series. Isr Med Assoc J 18:238–242

    PubMed  Google Scholar 

  12. Vitale A, Rigante D, Lopalco G et al (2016) New therapeutic solutions for Behçet’s syndrome. Expert Opin Investig Drugs 25:827–840. doi:10.1080/13543784.2016.1181751

    Article  CAS  PubMed  Google Scholar 

  13. Emmi G, Talarico R, Lopalco G et al (2016) Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol 35:1281–1286. doi:10.1007/s10067-015-3004-0

    Article  PubMed  Google Scholar 

  14. Fabiani C, Vitale A, Emmi G et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:191–197. doi:10.1007/s10067-016-3506-4

    Article  PubMed  Google Scholar 

  15. Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74. doi:10.1016/j.jaut.2015.06.005

    Article  CAS  PubMed  Google Scholar 

  16. Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183–189. doi:10.1007/s10067-016-3480-x

    Article  PubMed  Google Scholar 

  17. Vitale A, Emmi G, Lopalco G et al (2017) Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451–455. doi:10.1007/s10067-016-3417-4

    Article  PubMed  Google Scholar 

  18. Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105

    CAS  PubMed  Google Scholar 

  19. Ma D, Zhang CJ, Wang RP, Wang L, Yang H (2014) Etanercept in the treatment of intestinal Behcet’s disease. Cell Biochem Biophys 69:735–739. doi:10.1007/s12013-014-9860-4

    Article  CAS  PubMed  Google Scholar 

  20. Alty JE, Monaghan TM, Bamford JM (2007) A patient with neuro-Behçet’s disease is successfully treated with etanercept: further evidence for the value of TNF alpha blockade. Clin Neurol Neurosurg 109:279–281. doi:10.1016/j.clineuro.2006.11.002

    Article  PubMed  Google Scholar 

  21. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M (2009) Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol 22:551–555. doi:10.1177/039463200902200235

    Article  CAS  PubMed  Google Scholar 

  22. Mohammed RH (2014) Etanercept therapy in Behçet’s disease. The tight control strategy in refractory disease. Z Rheumatol 73:650–656. doi:10.1007/s00393-013-1307-6

    Article  CAS  PubMed  Google Scholar 

  23. Mesquida M, Victoria Hernández M, Llorenç V et al (2013) Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21:160–162. doi:10.3109/09273948.2012.741744

    Article  CAS  PubMed  Google Scholar 

  24. Cantarini L, Lopalco G, Vitale A et al (2015) Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab. Clin Rheumatol 34:1141–1143. doi:10.1007/s10067-014-2589-z

    Article  PubMed  Google Scholar 

  25. Belluzzo M, Dozzo M, Pigatto E, Schiavon F, Monti F (2014) A case of neuromyotonia in Behçet disease during TNF-α antagonist therapy. Neurol Sci 35:1637–1639. doi:10.1007/s10072-014-1820-7

    Article  PubMed  Google Scholar 

  26. Santos-Gómez M, Calvo-Río V, Blanco R et al (2016) The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol 34:S34–S40

    PubMed  Google Scholar 

  27. Cordero-Coma M, Calvo-Río V, Adán A et al (2014) Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediat Inflamm 2014:717598. doi:10.1155/2014/717598

    Article  CAS  Google Scholar 

  28. Olivieri I, Leccese P, D’Angelo S et al (2011) Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29:S54–S57

    PubMed  Google Scholar 

  29. Calvo-Río V, Blanco R, Beltrán E et al (2014) Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53:2223–2231. doi:10.1093/rheumatology/keu266

    Article  Google Scholar 

  30. Tanida S, Inoue N, Kobayashi K, et al (2015) Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease. Clin Gastroenterol Hepatol 13:940-8.e3. doi: 10.1016/j.cgh.2014.08.042.

    Article  Google Scholar 

  31. Hibi T, Hirohata S, Kikuchi H et al (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95:e3863. doi:10.1097/MD.0000000000003863

    Article  CAS  Google Scholar 

  32. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–70. doi:10.1016/j.semarthrit.2010.09.002

    Article  CAS  PubMed  Google Scholar 

  33. Luchetti MM, Balloni A, Gabrielli A (2016) Biologic therapy in inflammatory and Immunomediated arthritis: safety profile. Curr Drug Saf 11:22–34

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

    Antonio Vitale, Stefano Gentileschi, Bruno Frediani, Mauro Galeazzi & Luca Cantarini

  2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Giacomo Emmi, Elena Silvestri & Di Scala Gerardo

  3. Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

    Giuseppe Lopalco, Florenzo Iannone & Giovanni Lapadula

  4. Department of Ophthalmology, Humanitas Clinical and Research Center, via Manzoni 56, 20089, Rozzano, Milan, Italy

    Claudia Fabiani

  5. Institute of Pediatrics, Fondazione Policlinico Universitario “A. Gemelli”, Università Cattolica Sacro Cuore, Rome, Italy

    Donato Rigante

  6. Rheumatology Unit, Policlinico “Le Scotte”, University of Siena, viale Bracci 1, 53100, Siena, Italy

    Luca Cantarini

Authors
  1. Antonio Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giacomo Emmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Lopalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Fabiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefano Gentileschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elena Silvestri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Di Scala Gerardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Florenzo Iannone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bruno Frediani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mauro Galeazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Giovanni Lapadula
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Donato Rigante
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Claudia Fabiani or Luca Cantarini.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vitale, A., Emmi, G., Lopalco, G. et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease. Clin Rheumatol 36, 2063–2069 (2017). https://doi.org/10.1007/s10067-017-3627-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3627-4

Keywords

Search

Navigation